Table 1 Demographic and clinical characteristics of participants recruited in analyses from CAPOC, CAPEC, and SGE (as healthy control, HC)
Item | CAPOC (n = 2307) | CAPEC (n = 1379) | HC (n = 275) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Olanzapine (n = 398) | Aripiprazole (n = 386) | Risperidone (n = 394) | Quetiapine (n = 375) | Haloperidol (n = 175) | Ziprasidone (n = 386) | Perphenazine (n = 193) | Olanzapine (n = 459) | Aripiprazole (n = 462) | Risperidone (n = 458) | / | |
Male [n (%)] | 200(50.3) | 185(47.9) | 228(57.9) | 176(46.9) | 85(48.6) | 193(50.0) | 89(46.1) | 245(53.4) | 235(50.9) | 232(50.7) | 137(50.1) |
Age (years, mean ± SD) | 30.2 ± 7.9 | 31.1 ± 7.8 | 30.6 ± 7.9 | 30.8 ± 7.7 | 32.7 ± 7.6 | 30.3 ± 7.9 | 31.8 ± 8.0 | 31.6 ± 6.3 | 32.8 ± 11.3 | 32.4 ± 10.4 | 24.7 ± 3.2 |
Baseline PANSS total score (mean ± SD) | 88.6 ± 15.3 | 89.3 ± 15.0 | 89.3 ± 14.8 | 91.0 ± 15.1 | 90.9 ± 16.0 | 91.0 ± 15.4 | 92.33 ± 15.7 | 104.5 ± 22.5 | 94.1 ± 18.1 | 86.0 ± 13.5 | – |
Endpoint PANSS total score (mean ± SD) | 54.2 ± 14.7 | 59.0 ± 19.0 | 54.4 ± 14.2 | 59.1 ± 17.1 | 57.0 ± 15.7 | 61.1 ± 18.0 | 60.5 ± 18.7 | 69.8 ± 22.8 | 67.3 ± 18.1 | 59.9 ± 16.9 | – |
PANSS reduction rate (mean ± SD) | 55.9 ± 24.7 | 47.8 ± 29.1 | 55.3 ± 25.0 | 48.2 ± 28.2 | 53.4 ± 24.2 | 46.6 ± 28.2 | 49.2 ± 27.8 | 48.0 ± 22.9 | 41.6 ± 22.5 | 47.1 ± 26.0 | – |
RES [n (%)] | 253(63.6) | 189(49.0) | 252(64.0) | 191(50.9) | 102(58.3) | 181(46.9) | 103(53.4) | 268(58.4) | 278(60.2) | 280(61.1) | – |
Follow-up (week) | 6 | 8 | – | ||||||||